Adamis Appoints Vickie Reed to Board of Directors
May 26 2022 - 4:05PM
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today
announced the appointment of Vickie Reed as a new director and
member of the company’s board of directors.
Richard Williams, Chairman of the Board, commented: “We are
pleased to welcome Ms. Reed to the Board and look forward to
working with her to pursue long-term stockholder value. Her
substantial expertise as a healthcare executive in financial
leadership roles at several public companies, and extensive
background in finance and accounting, combined with her experience
as a director of another public life science company, should allow
her to have an immediate positive impact as Adamis executes on its
corporate strategies.”
“I am looking forward to working with other members of the
Adamis Board of Directors and the management team to advance the
company’s goals and further its corporate, regulatory and
commercial strategies,” said Ms. Reed.
Ms. Reed currently serves as Senior Vice President, Finance and
Chief Accounting Officer at Mirati Therapeutics where she
previously held the positions of Chief Accounting Officer, Vice
President of Finance and Senior Director and Corporate Controller.
She is also a member of the board of directors of Evoke Pharma.
Previously, she served as Senior Director, Finance and Controller
at Zogenix, Inc., a public biotechnology company in San Diego and
Emeryville, California, and held corporate accounting positions at
Amylin Pharmaceuticals, Inc., a public biotechnology company
acquired by Bristol Myers Squibb in 2012. Prior to joining Amylin,
Ms. Reed held financial leadership roles at several
biotechnology and telecommunications companies. Ms. Reed began
her career with Price Waterhouse, now PricewaterhouseCoopers, in
Denver, Colorado. She is a Certified Public Accountant (inactive)
in the State of Colorado and received a B.S. in Accounting from the
University of Colorado, Denver.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. The
Company’s SYMJEPI® (epinephrine) Injection products are
approved by the FDA for use in the emergency treatment of acute
allergic reactions, including anaphylaxis. The
Company’s ZIMHI™ (naloxone) Injection product is approved
for the treatment of opioid overdose. Tempol is in development for
the treatment of patients with COVID-19 and a Phase 2/3 clinical
trial is underway. For additional information about Adamis
Pharmaceuticals, please visit our website and follow us
on Twitter and LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include those that express
plans, anticipation, intent, contingencies, goals, targets or
future development and/or otherwise are not statements of
historical fact. These statements relate to future events or future
results of operations, including, but not limited to, statements
concerning the Company’s future operations and activities. These
statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, which may cause Adamis'
actual results to be materially different from the results
anticipated by such forward-looking statements. We cannot assess
the impact of each factor on our business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. You should not place undue reliance on any
forward-looking statements. Further, any forward-looking statement
speaks only as of the date on which it is made, and except as may
be required by applicable law, we undertake no obligation to update
or release publicly the results of any revisions to these
forward-looking statements or to reflect events or circumstances
arising after the date of this press release. Certain of these
risks and additional risks, uncertainties, and other factors are
described in greater detail in Adamis’ filings from time to time
with the SEC, including its annual report on Form 10-K for the year
ended December 31, 2021 and subsequent filings with the SEC, which
Adamis strongly urges you to read and consider, all of which are
available free of charge on the SEC's website
at http://www.sec.gov.
Contact:
Adamis Investor RelationsRobert UhlManaging DirectorWestwicke
ICR619.228.5886robert.uhl@westwicke.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Sep 2023 to Sep 2024